Oct 14, 2019
Immutep Reports Positive Final Efficacy Data from TACTI-mel Trial in Melanoma
Oct 09, 2019
Immutep Announces Data Presentations at Upcoming Industry Conferences
Immutep Receives A$2.5 Million R&D Tax Incentive from French Government
Sep 25, 2019
Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim Data
Sep 22, 2019
Immutep to Receive £4M Milestone Payment from GSK
